366 related articles for article (PubMed ID: 33071055)
21. An Antibacterial β-Lactone Kills Mycobacterium tuberculosis by Disrupting Mycolic Acid Biosynthesis.
Lehmann J; Cheng TY; Aggarwal A; Park AS; Zeiler E; Raju RM; Akopian T; Kandror O; Sacchettini JC; Moody DB; Rubin EJ; Sieber SA
Angew Chem Int Ed Engl; 2018 Jan; 57(1):348-353. PubMed ID: 29067779
[TBL] [Abstract][Full Text] [Related]
22. Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
Coulibaly S; Cimino M; Ouattara M; Lecoutey C; Buchieri MV; Alonso-Rodriguez N; Briffotaux J; Mornico D; Gicquel B; Rochais C; Dallemagne P
Eur J Med Chem; 2020 Dec; 207():112821. PubMed ID: 32950907
[TBL] [Abstract][Full Text] [Related]
23. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
[TBL] [Abstract][Full Text] [Related]
24. Dissecting the antibacterial activity of oxadiazolone-core derivatives against Mycobacterium abscessus.
Madani A; Mallick I; Guy A; Crauste C; Durand T; Fourquet P; Audebert S; Camoin L; Canaan S; Cavalier JF
PLoS One; 2020; 15(9):e0238178. PubMed ID: 32946441
[TBL] [Abstract][Full Text] [Related]
25. Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis.
Urban M; Šlachtová V; Brulíková L
Eur J Med Chem; 2021 Feb; 212():113139. PubMed ID: 33422979
[TBL] [Abstract][Full Text] [Related]
26. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
27. A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus.
Dupont C; Viljoen A; Dubar F; Blaise M; Bernut A; Pawlik A; Bouchier C; Brosch R; Guérardel Y; Lelièvre J; Ballell L; Herrmann JL; Biot C; Kremer L
Mol Microbiol; 2016 Aug; 101(3):515-29. PubMed ID: 27121350
[TBL] [Abstract][Full Text] [Related]
28. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
29. Altered drug efflux under iron deprivation unveils abrogated MmpL3 driven mycolic acid transport and fluidity in mycobacteria.
Pal R; Hameed S; Fatima Z
Biometals; 2019 Feb; 32(1):49-63. PubMed ID: 30430296
[TBL] [Abstract][Full Text] [Related]
30. Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.
Sharma A; Khuller GK; Sharma S
Expert Opin Ther Targets; 2009 Jul; 13(7):753-65. PubMed ID: 19530983
[TBL] [Abstract][Full Text] [Related]
31. Current status and future development of antitubercular chemotherapy.
Kremer LS; Besra GS
Expert Opin Investig Drugs; 2002 Aug; 11(8):1033-49. PubMed ID: 12150700
[TBL] [Abstract][Full Text] [Related]
32. New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.
North EJ; Jackson M; Lee RE
Curr Pharm Des; 2014; 20(27):4357-78. PubMed ID: 24245756
[TBL] [Abstract][Full Text] [Related]
33. In Vitro Anti-mycobacterial Activity of Three Medicinal Plants of Lamiaceae Family.
Kazemian H; Heidari H; Yamchi JK; Zandi H; Taji A; Yazdani F; Hamzehloo G; Ghanavati R; Rahdar HA; Feizabadi MM
Recent Pat Antiinfect Drug Discov; 2018; 13(3):240-245. PubMed ID: 29952265
[TBL] [Abstract][Full Text] [Related]
34. Isolation and characterization of nontuberculous mycobacteria from patients with pulmonary tuberculosis in Ghana.
Otchere ID; Asante-Poku A; Osei-Wusu S; Aboagye SY; Yeboah-Manu D
Int J Mycobacteriol; 2017; 6(1):70-75. PubMed ID: 28317808
[TBL] [Abstract][Full Text] [Related]
35. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
[TBL] [Abstract][Full Text] [Related]
36. Identification of inhibitors against Mycobacterium tuberculosis thiamin phosphate synthase, an important target for the development of anti-TB drugs.
Khare G; Kar R; Tyagi AK
PLoS One; 2011; 6(7):e22441. PubMed ID: 21818324
[TBL] [Abstract][Full Text] [Related]
37. Design of Novel Phosphopantetheine Adenylyltransferase Inhibitors: A Potential New Approach to Tackle Mycobacterium tuberculosis.
Primi MC; Tavares MT; Klein LL; Izard T; Sant'Anna CMR; Franzblau SG; Ferreira EI
Curr Top Med Chem; 2021; 21(13):1186-1197. PubMed ID: 34323186
[TBL] [Abstract][Full Text] [Related]
38. Nontoxic Metal-Cyclam Complexes, a New Class of Compounds with Potency against Drug-Resistant Mycobacterium tuberculosis.
Yu M; Nagalingam G; Ellis S; Martinez E; Sintchenko V; Spain M; Rutledge PJ; Todd MH; Triccas JA
J Med Chem; 2016 Jun; 59(12):5917-21. PubMed ID: 27214150
[TBL] [Abstract][Full Text] [Related]
39. Evidence for Inhibition of Topoisomerase 1A by Gold(III) Macrocycles and Chelates Targeting Mycobacterium tuberculosis and Mycobacterium abscessus.
Gupta R; Rodrigues Felix C; Akerman MP; Akerman KJ; Slabber CA; Wang W; Adams J; Shaw LN; Tse-Dinh YC; Munro OQ; Rohde KH
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483110
[No Abstract] [Full Text] [Related]
40. Targeting intracellular nontuberculous mycobacteria and
Bartlett HP; Dawson CC; Glickman CM; Osborn DW; Evans CR; Garcia BJ; Frost LC; Cummings JE; Whittel N; Slayden RA; Holder JW
Microbiol Spectr; 2024 May; 12(5):e0353423. PubMed ID: 38534149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
